-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52

Benzinga·11/09/2026 08:44:02
  • ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population
  • First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies
  • Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity